{
  "legislationId": "119_S_4227",
  "lastUpdate": "2026-04-13T14:57:56.912Z",
  "history": [
    {
      "timestamp": "2026-04-13T14:57:56.912Z",
      "source_url": "https://www.congress.gov/119/bills/s4227/BILLS-119s4227is.htm",
      "model": "gemini-flash-lite-latest",
      "prompt_sent": "\nROLE: Fact Checker.\nZADANIE: Porównaj SOURCE (oryginał) i SUMMARY (streszczenie przygotowane przez inne AI).\n\nTwoim celem jest wykrycie \"ZMYŚLONYCH KONKRETÓW\" (Fabricated Entities) w SUMMARY.\n\nSOURCE:\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 4227 Introduced in Senate (IS)] <DOC> 119th CONGRESS 2d Session S. 4227 To require the Secretary of Health and Human Services, acting through the Assistant Secretary for Preparedness and Response, to carry out a program under which the Secretary requires each covered distributor of a highly pathogenic agent to comply with certain logbook requirements, and for other purposes. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES March 26, 2026 Ms. Cortez Masto (for herself and Mr. Banks) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions _______________________________________________________________________ A BILL To require the Secretary of Health and Human Services, acting through the Assistant Secretary for Preparedness and Response, to carry out a program under which the Secretary requires each covered distributor of a highly pathogenic agent to comply with certain logbook requirements, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Preventing Illegal Laboratories and Protecting Public Health Act of 2026''. SEC. 2. REQUIRING CERTAIN DISTRIBUTORS OF HIGHLY PATHOGENIC AGENTS TO KEEP A LOGBOOK OF SALES, LEASES, LOANS, AND OTHER TRANSFERS. (a) Program.--The Secretary shall carry out a program under which the Secretary requires each covered distributor of a highly pathogenic agent to comply with the logbook requirements of subsection (c). (b) List of Highly Pathogenic Agents.-- (1) Development.--The Secretary shall develop and maintain a list of all agents that meet the definition of a highly pathogenic agent in subsection (e). (2) Initial list.--The Secretary shall develop the initial list required by paragraph (1) not later than 6 months after the date of enactment of this Act. (3) Periodic review.--The Secretary shall annually review and update the list required by paragraph (1). (4) Consultation; consideration.--In developing and updating the list required by paragraph (1), the Secretary shall-- (A) consult with relevant agencies, including the Centers for Disease Control and Prevention, the National Institutes of Health, the Department of Homeland Security, the Department of Agriculture, the Department of the Interior, and the Department of Defense; (B) take into consideration the latest edition of ``Biosafety in Microbiological and Biomedical Laboratories'' published by the Centers for Disease Control and Prevention and the National Institutes of Health (or any successor to such publication); and (C) take into consideration the latest edition of ``NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules'' published by the National Institutes of Health (or any successor to such publication). (c) Logbook Requirements.-- (1) In general.--Each covered distributor shall maintain, in accordance with such criteria and format as the Secretary may require, an electronic list (in this section referred to as a ``logbook'') of the sales, leases, loans, or other transfers by such distributor of each highly pathogenic agent on the list under subsection (b). (2) Contents.--The covered distributor shall, for each sale, lease, loan, or other transfer referred to in paragraph (1), include in the logbook-- (A) the agent by name; (B) the name, address, telephone number, and email address of the purchaser; (C) other relevant identifying business information of the purchaser, as the Secretary determines appropriate; (D) a short description of-- (i) the purchaser's intended use of the highly pathogenic agent; and (ii) where the purchaser will house the agent; (E) the date and time of the sale, lease, loan, or other transfer; (F) the method, date, and time of transfer of the highly pathogenic agent; (G) a physical or electronic signature of the purchaser; and (H) such other data elements as the Secretary may require. (3) Sale requirements.--In the case of a sale, lease, loan, or other transfer to which paragraph (1) applies, the covered distributor shall not sell the highly pathogenic agent unless-- (A) the prospective purchaser, in physical form or electronically in compliance with the Electronic Signatures in Global and National Commerce Act (42 U.S.C. 7001 et seq.)-- (i) presents an identification card that provides a photograph and is issued by a State or the Federal Government, or a document that, with respect to identification, is considered acceptable for purposes of sections 274a.2(b)(1)(v)(A) and 274a.2(b)(1)(v)(B) of title 8, Code of Federal Regulations (or successor regulations); and (ii) verifies by signature in the logbook-- (I) the purchaser's name and address; (II) a short description of-- (aa) the purchaser's intended use of the agent; and (bb) where the purchaser will house the agent; (III) the date and time of the sale, lease, loan, or other transfer; and (IV) the method, date, and time of transfer of the agent; and (B) the covered distributor-- (i) determines that the name entered in the logbook corresponds to the name provided on the identification card described in subparagraph (A)(i), and that the information entered pursuant to subparagraph (A)(ii) is correct; and (ii) enters in the logbook the name of the highly pathogenic agent. (4) Notice.--The covered distributor shall include in the logbook, in accordance with criteria of the Secretary, a notice to purchasers that entering false statements or misrepresentations in the logbook may subject the purchasers to criminal penalties under section 1001 of title 18, United States Code, which notice specifies the maximum fine and term of imprisonment under such section. (5) Duration of maintenance of entries.-- (A) Retention period.--The covered distributor shall maintain each entry in the logbook for not fewer than 3 years after the date on which the entry is made. (B) Successor entity.--If ownership of a covered distributor changes, the successor entity shall assume custody of and responsibility for all logbooks for the remainder of the 3-year retention period required by subparagraph (A). (6) Disclosure of logbooks.--The Secretary shall establish restrictions on disclosure of information in logbooks. Such regulations shall-- (A) provide for the disclosure of the information, as appropriate, to the Secretary, Federal, State, local, Tribal, and territorial law enforcement agencies, and State health officials; and (B) prohibit accessing, using, or sharing information in the logbooks for any purpose other than-- (i) to ensure compliance with this section; (ii) to protect public health and safety; or (iii) to protect national security. (7) FOIA exemption.--Logbooks and any derivative data are exempt from disclosure under section 552(b)(3) of title 5, United States Code. (8) Applicability.--A transfer of a highly pathogenic agent between laboratories within a single institution of higher education (as defined in section 101 of the Higher Education Act of 1965 (20 U.S.C. 1001)) does not constitute a sale, lease, loan, or other transfer of the agent for purposes of paragraph (1). (9) Audits.--The Secretary shall establish a risk-based compliance review process by which the Secretary may conduct audits of logbooks when the Secretary has cause to believe a violation of this section has occurred. The Secretary shall focus audits conducted under this paragraph on higher-risk distributors and suspicious patterns. (d) False Statements or Misrepresentations by Purchasers.--For purposes of section 1001 of title 18, United States Code, providing information to a covered distributor for purposes of entering such information in a logbook shall be considered a matter within the jurisdiction of the executive, legislative, or judicial branch of the Government of the United States. (e) Definitions.--In this section: (1) The term ``covered distributor''-- (A) means an entity that sells, leases, loans, or otherwise transfers for value or not for value a highly pathogenic agent, except that such term does not include an employee or agent of such a distributor; and (B) includes a publicly funded repository or biobank that sells, leases, loans, or otherwise transfers a highly pathogenic agent, as described in subparagraph (A). (2) The term ``highly pathogenic agent''-- (A) subject to subparagraph (B), means a pathogenic agent that meets the criteria of ``risk group 3'' or any higher level risk groups as such risk groups are defined in the latest edition of ``NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules'' published by the National Institutes of Health (or any successor to such publication); and (B) excludes any biological agent or toxin that is regulated under section 351A of the Public Health Service Act (42 U.S.C. 262a) or section 212 of the Agricultural Bioterrorism Protection Act of 2002 (7 U.S.C. 8401). (3) The term ``Secretary'' means the Secretary of Health and Human Services, acting through the Assistant Secretary for Strategic Preparedness and Response. (f) Rule of Construction.--Nothing in this section shall be construed to supersede or otherwise affect the Federal Select Agent Program under section 351A of the Public Health Service Act (42 U.S.C. 262a) and section 212 of the Agricultural Bioterrorism Protection Act of 2002 (7 U.S.C. 8401). SEC. 3. EVALUATION OF HIGH-CONTAINMENT LABORATORIES. (a) In General.--The National Security Advisor, in consultation with the Secretary of Health and Human Services, the Secretary of Agriculture, the Secretary of Defense, the Secretary of Homeland Security, the Secretary of the Interior, the Director of National Intelligence, and such other Federal officials as the National Security Advisor determines appropriate, shall identify a single Federal entity to oversee a periodic strategic evaluation of high-containment laboratories in the United States. (b) Topics.--Each strategic evaluation under subsection (a) shall include-- (1) an assessment of-- (A) the number, location, and mission of high- containment laboratories; (B) the capacity of such existing laboratories to effectively meet national goals to counter threats to biosafety and biosecurity; (C) the physical security measures at high- containment laboratories; (D) the aggregate risks associated with-- (i) such existing laboratories; and (ii) expanding the numbers and facilities of such laboratories; and (E) the type of oversight needed for high- containment laboratories; and (2) up-to-date national standards, developed by the Federal entity identified under subsection (a), that-- (A) are developed by the Federal entity identified under subsection (a) in consultation with members of the scientific community, for the design, construction, commissioning, operation, and long-term maintenance of high-containment laboratories; and (B) take into consideration applicable regulations and guidance for high-containment laboratories. (c) Reporting.--Upon completion of each strategic evaluation under subsection (a), the Federal entity identified under subsection (a) shall submit to the President and to Congress a report on the results of such evaluation and include in each such report recommendations on-- (1) addressing gaps in Federal oversight of high- containment laboratories; and (2) utilizing high-containment laboratories for protecting public health and ensuring biosafety and biosecurity in the United States. (d) Public Health Biosafety and Biosecurity Team.-- (1) In general.--The Federal entity identified under subsection (a) shall maintain a team, to be known as the Public Health Biosafety and Biosecurity Team, to serve as a single point of contact for State, local, Tribal, and territorial agencies regarding questions relating to laboratory biosafety and biosecurity. (2) Establishment.--The Federal entity identified under subsection (a) shall establish the Public Health and Biosecurity Team, as required by paragraph (1), not later than one year after such official is first designated. (3) Duties.--The Public Health Biosafety and Biosecurity Team shall be the single point of contact in the Federal Government for State, local, Tribal, and territorial agencies on-- (A) issues related to-- (i) oversight of high-containment laboratories; (ii) the impact of high-containment laboratories on public health; or (iii) connecting State, local, Tribal, and territorial officials with the relevant Federal agency or agencies on matters related to high- containment laboratories; and (B) other issues as the Federal entity identified under subsection (a) determines appropriate. (e) Feasibility Study.-- (1) In general.--The Federal entity identified under subsection (a) shall conduct a feasibility study on establishing and maintaining a database on existing high- containment laboratories in the United States for the purpose of making such database accessible to Federal, State, local, Tribal, and territorial officials. (2) Database described.--The database considered under paragraph (1) shall be a database designed to include, with respect to each high-containment laboratory, the following information: (A) The identity of the owners of the laboratory. (B) The address of the laboratory. (C) The status of any licensing or certification of the laboratory required under Federal, State, local, Tribal, or territorial law. (D) Any legal violations by, and disciplinary action taken against, the laboratory. (E) Such additional information as the Federal entity identified under subsection (a) determines appropriate to protect biosafety and biosecurity. (3) Report to congress.--Upon completion of the feasibility study under this subsection, the Federal entity identified under subsection (a) shall submit to Congress a report on the results of such study. (f) Definition.--In this section, the term ``high-containment laboratory'' means a laboratory that is suitable for ``biosafety level 3'' or any higher biosafety level procedures, as defined in the latest edition of ``Biosafety in Microbiological and Biomedical Laboratories'' published by the Centers for Disease Control and Prevention and the National Institutes of Health (or any successor to such publication). <all>\n\nSUMMARY TO EVALUATE:\nTitle: Preventing Illegal Laboratories and Protecting Public Health Act of 2026\nSummary: This act establishes strict tracking for dangerous pathogens and increases oversight of high-security laboratories. It aims to protect public health by ensuring that hazardous biological agents are only sold to verified individuals for legitimate purposes.\nKey Points: Mandatory electronic logbooks for the sale, lease, or transfer of highly dangerous pathogens., Requirement for identity verification and detailed descriptions of the purchaser's intended use and storage location., Criminal penalties for providing false information when acquiring hazardous biological agents., Establishment of national safety standards and strategic evaluations for high-containment laboratories., Creation of a federal biosafety support team to assist state and local agencies with security concerns.\n\nZASADY OCENY:\n1. Sprawdź wszystkie LICZBY, DATY i KWOTY w SUMMARY. Jeśli którejś brakuje w SOURCE -> is_valid: false.\n2. Sprawdź wszystkie NAZWISKA, ORGANIZACJE i MIEJSCA w SUMMARY. Jeśli którejś brakuje w SOURCE -> is_valid: false.\n3. Sprawdź wszystkie konkretne DZIAŁANIA PRAWNE . Jeśli tego mechanizmu nie ma w SOURCE -> is_valid: false.\n\nWAŻNE: Abstrakcyjne pojęcia (np. \"transparentność\", \"zaufanie\") są dozwolone jako wnioski.\n\nOUTPUT (JSON):\n{\n  \"is_valid\": true/false,\n  \"issue\": \"fabricated_entity\" / \"contradiction\" / \"none\"\n}\n\nWYMAGANIA FORMATOWANIA:\n1. Odpowiedz WYŁĄCZNIE surowym obiektem JSON.\n2. NIE używaj bloków kodu Markdown.\n3. NIE dodawaj żadnych wstępów ani wyjaśnień przed ani po JSONie.\n4. JSON musi być poprawny i gotowy do parsowania.\n\n",
      "ai_response_raw": "{\n  \"is_valid\": true,\n  \"issue\": \"none\"\n}"
    },
    {
      "timestamp": "2026-04-13T14:25:11.523Z",
      "source_url": "https://www.congress.gov/119/bills/s4227/BILLS-119s4227is.htm",
      "model": "gemini-flash-latest",
      "prompt_sent": "\nJesteś ekspertem od prawa Stanów Zjednoczonych, który ma za zadanie analizować dokumenty ustaw, uchwał oraz innych dokumentów legislacyjnych, a następnie przygotowywać z nich informacje w przystępny sposób dla obywateli. Twoim celem jest przedstawienie informacji tak, aby obywatele mogli sami ocenić wpływ legislacji na ich życie, nawet bez posiadania specjalistycznej wiedzy legislacyjnej. Skup się na faktach i obiektywnych skutkach wprowadzanych zmian, unikając wartościowania i osobistych opinii. Wszelki żargon prawny jest zabroniony. Prezentuj informacje w jasny, zwięzły i angażujący sposób, tak aby były zrozumiałe dla osoby bez wykształcenia prawniczego. Unikaj długich, złożonych zdań. Zamiast pisać \"projekt ma na celu nowelizację kodeksu podatkowego...\", napisz \"Zmiany w podatkach: nowe ulgi i obowiązki dla...\". Kontynuuj swoją pracę, dopóki nie rozwiążesz swojego zadania. Jeśli nie masz pewności co do generowanej treści, przeanalizuj dokument ponownie – nie zgaduj. Rozplanuj dobrze swoje zadanie przed przystąpieniem do niego. W podsumowaniu i kluczowych punktach, jeśli to możliwe i uzasadnione, podkreśl, jakie konkretne korzyści lub skutki (pozytywne lub negatywne) wprowadza ustawa dla życia codziennego obywateli, ich praw i obowiązków, finansów osobistych, bezpieczeństwa i innych ważnych kwestii (np. kategorycznych zakazów i nakazów czy najważniejszych konkretnych alokacji finansowych i terytorialnych).\n\nTwoja odpowiedź MUSI być w formacie JSON - i zawierać następujące klucze.\nZanim zwrócisz odpowiedź, dokładnie zweryfikuj, czy cała struktura JSON jest w 100% poprawna, włącznie ze wszystkimi przecinkami, nawiasami klamrowymi, kwadratowymi oraz cudzysłowami. Błędny JSON jest nieakceptowalny i uniemożliwi przetworzenie Twojej pracy.\n\nPrzeanalizuj dokładnie poniższy tekst dokumentu prawnego. To jest treść, na podstawie której masz wygenerować podsumowanie i kluczowe punkty:\n--- POCZĄTEK DOKUMENTU ---\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 4227 Introduced in Senate (IS)] <DOC> 119th CONGRESS 2d Session S. 4227 To require the Secretary of Health and Human Services, acting through the Assistant Secretary for Preparedness and Response, to carry out a program under which the Secretary requires each covered distributor of a highly pathogenic agent to comply with certain logbook requirements, and for other purposes. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES March 26, 2026 Ms. Cortez Masto (for herself and Mr. Banks) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions _______________________________________________________________________ A BILL To require the Secretary of Health and Human Services, acting through the Assistant Secretary for Preparedness and Response, to carry out a program under which the Secretary requires each covered distributor of a highly pathogenic agent to comply with certain logbook requirements, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Preventing Illegal Laboratories and Protecting Public Health Act of 2026''. SEC. 2. REQUIRING CERTAIN DISTRIBUTORS OF HIGHLY PATHOGENIC AGENTS TO KEEP A LOGBOOK OF SALES, LEASES, LOANS, AND OTHER TRANSFERS. (a) Program.--The Secretary shall carry out a program under which the Secretary requires each covered distributor of a highly pathogenic agent to comply with the logbook requirements of subsection (c). (b) List of Highly Pathogenic Agents.-- (1) Development.--The Secretary shall develop and maintain a list of all agents that meet the definition of a highly pathogenic agent in subsection (e). (2) Initial list.--The Secretary shall develop the initial list required by paragraph (1) not later than 6 months after the date of enactment of this Act. (3) Periodic review.--The Secretary shall annually review and update the list required by paragraph (1). (4) Consultation; consideration.--In developing and updating the list required by paragraph (1), the Secretary shall-- (A) consult with relevant agencies, including the Centers for Disease Control and Prevention, the National Institutes of Health, the Department of Homeland Security, the Department of Agriculture, the Department of the Interior, and the Department of Defense; (B) take into consideration the latest edition of ``Biosafety in Microbiological and Biomedical Laboratories'' published by the Centers for Disease Control and Prevention and the National Institutes of Health (or any successor to such publication); and (C) take into consideration the latest edition of ``NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules'' published by the National Institutes of Health (or any successor to such publication). (c) Logbook Requirements.-- (1) In general.--Each covered distributor shall maintain, in accordance with such criteria and format as the Secretary may require, an electronic list (in this section referred to as a ``logbook'') of the sales, leases, loans, or other transfers by such distributor of each highly pathogenic agent on the list under subsection (b). (2) Contents.--The covered distributor shall, for each sale, lease, loan, or other transfer referred to in paragraph (1), include in the logbook-- (A) the agent by name; (B) the name, address, telephone number, and email address of the purchaser; (C) other relevant identifying business information of the purchaser, as the Secretary determines appropriate; (D) a short description of-- (i) the purchaser's intended use of the highly pathogenic agent; and (ii) where the purchaser will house the agent; (E) the date and time of the sale, lease, loan, or other transfer; (F) the method, date, and time of transfer of the highly pathogenic agent; (G) a physical or electronic signature of the purchaser; and (H) such other data elements as the Secretary may require. (3) Sale requirements.--In the case of a sale, lease, loan, or other transfer to which paragraph (1) applies, the covered distributor shall not sell the highly pathogenic agent unless-- (A) the prospective purchaser, in physical form or electronically in compliance with the Electronic Signatures in Global and National Commerce Act (42 U.S.C. 7001 et seq.)-- (i) presents an identification card that provides a photograph and is issued by a State or the Federal Government, or a document that, with respect to identification, is considered acceptable for purposes of sections 274a.2(b)(1)(v)(A) and 274a.2(b)(1)(v)(B) of title 8, Code of Federal Regulations (or successor regulations); and (ii) verifies by signature in the logbook-- (I) the purchaser's name and address; (II) a short description of-- (aa) the purchaser's intended use of the agent; and (bb) where the purchaser will house the agent; (III) the date and time of the sale, lease, loan, or other transfer; and (IV) the method, date, and time of transfer of the agent; and (B) the covered distributor-- (i) determines that the name entered in the logbook corresponds to the name provided on the identification card described in subparagraph (A)(i), and that the information entered pursuant to subparagraph (A)(ii) is correct; and (ii) enters in the logbook the name of the highly pathogenic agent. (4) Notice.--The covered distributor shall include in the logbook, in accordance with criteria of the Secretary, a notice to purchasers that entering false statements or misrepresentations in the logbook may subject the purchasers to criminal penalties under section 1001 of title 18, United States Code, which notice specifies the maximum fine and term of imprisonment under such section. (5) Duration of maintenance of entries.-- (A) Retention period.--The covered distributor shall maintain each entry in the logbook for not fewer than 3 years after the date on which the entry is made. (B) Successor entity.--If ownership of a covered distributor changes, the successor entity shall assume custody of and responsibility for all logbooks for the remainder of the 3-year retention period required by subparagraph (A). (6) Disclosure of logbooks.--The Secretary shall establish restrictions on disclosure of information in logbooks. Such regulations shall-- (A) provide for the disclosure of the information, as appropriate, to the Secretary, Federal, State, local, Tribal, and territorial law enforcement agencies, and State health officials; and (B) prohibit accessing, using, or sharing information in the logbooks for any purpose other than-- (i) to ensure compliance with this section; (ii) to protect public health and safety; or (iii) to protect national security. (7) FOIA exemption.--Logbooks and any derivative data are exempt from disclosure under section 552(b)(3) of title 5, United States Code. (8) Applicability.--A transfer of a highly pathogenic agent between laboratories within a single institution of higher education (as defined in section 101 of the Higher Education Act of 1965 (20 U.S.C. 1001)) does not constitute a sale, lease, loan, or other transfer of the agent for purposes of paragraph (1). (9) Audits.--The Secretary shall establish a risk-based compliance review process by which the Secretary may conduct audits of logbooks when the Secretary has cause to believe a violation of this section has occurred. The Secretary shall focus audits conducted under this paragraph on higher-risk distributors and suspicious patterns. (d) False Statements or Misrepresentations by Purchasers.--For purposes of section 1001 of title 18, United States Code, providing information to a covered distributor for purposes of entering such information in a logbook shall be considered a matter within the jurisdiction of the executive, legislative, or judicial branch of the Government of the United States. (e) Definitions.--In this section: (1) The term ``covered distributor''-- (A) means an entity that sells, leases, loans, or otherwise transfers for value or not for value a highly pathogenic agent, except that such term does not include an employee or agent of such a distributor; and (B) includes a publicly funded repository or biobank that sells, leases, loans, or otherwise transfers a highly pathogenic agent, as described in subparagraph (A). (2) The term ``highly pathogenic agent''-- (A) subject to subparagraph (B), means a pathogenic agent that meets the criteria of ``risk group 3'' or any higher level risk groups as such risk groups are defined in the latest edition of ``NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules'' published by the National Institutes of Health (or any successor to such publication); and (B) excludes any biological agent or toxin that is regulated under section 351A of the Public Health Service Act (42 U.S.C. 262a) or section 212 of the Agricultural Bioterrorism Protection Act of 2002 (7 U.S.C. 8401). (3) The term ``Secretary'' means the Secretary of Health and Human Services, acting through the Assistant Secretary for Strategic Preparedness and Response. (f) Rule of Construction.--Nothing in this section shall be construed to supersede or otherwise affect the Federal Select Agent Program under section 351A of the Public Health Service Act (42 U.S.C. 262a) and section 212 of the Agricultural Bioterrorism Protection Act of 2002 (7 U.S.C. 8401). SEC. 3. EVALUATION OF HIGH-CONTAINMENT LABORATORIES. (a) In General.--The National Security Advisor, in consultation with the Secretary of Health and Human Services, the Secretary of Agriculture, the Secretary of Defense, the Secretary of Homeland Security, the Secretary of the Interior, the Director of National Intelligence, and such other Federal officials as the National Security Advisor determines appropriate, shall identify a single Federal entity to oversee a periodic strategic evaluation of high-containment laboratories in the United States. (b) Topics.--Each strategic evaluation under subsection (a) shall include-- (1) an assessment of-- (A) the number, location, and mission of high- containment laboratories; (B) the capacity of such existing laboratories to effectively meet national goals to counter threats to biosafety and biosecurity; (C) the physical security measures at high- containment laboratories; (D) the aggregate risks associated with-- (i) such existing laboratories; and (ii) expanding the numbers and facilities of such laboratories; and (E) the type of oversight needed for high- containment laboratories; and (2) up-to-date national standards, developed by the Federal entity identified under subsection (a), that-- (A) are developed by the Federal entity identified under subsection (a) in consultation with members of the scientific community, for the design, construction, commissioning, operation, and long-term maintenance of high-containment laboratories; and (B) take into consideration applicable regulations and guidance for high-containment laboratories. (c) Reporting.--Upon completion of each strategic evaluation under subsection (a), the Federal entity identified under subsection (a) shall submit to the President and to Congress a report on the results of such evaluation and include in each such report recommendations on-- (1) addressing gaps in Federal oversight of high- containment laboratories; and (2) utilizing high-containment laboratories for protecting public health and ensuring biosafety and biosecurity in the United States. (d) Public Health Biosafety and Biosecurity Team.-- (1) In general.--The Federal entity identified under subsection (a) shall maintain a team, to be known as the Public Health Biosafety and Biosecurity Team, to serve as a single point of contact for State, local, Tribal, and territorial agencies regarding questions relating to laboratory biosafety and biosecurity. (2) Establishment.--The Federal entity identified under subsection (a) shall establish the Public Health and Biosecurity Team, as required by paragraph (1), not later than one year after such official is first designated. (3) Duties.--The Public Health Biosafety and Biosecurity Team shall be the single point of contact in the Federal Government for State, local, Tribal, and territorial agencies on-- (A) issues related to-- (i) oversight of high-containment laboratories; (ii) the impact of high-containment laboratories on public health; or (iii) connecting State, local, Tribal, and territorial officials with the relevant Federal agency or agencies on matters related to high- containment laboratories; and (B) other issues as the Federal entity identified under subsection (a) determines appropriate. (e) Feasibility Study.-- (1) In general.--The Federal entity identified under subsection (a) shall conduct a feasibility study on establishing and maintaining a database on existing high- containment laboratories in the United States for the purpose of making such database accessible to Federal, State, local, Tribal, and territorial officials. (2) Database described.--The database considered under paragraph (1) shall be a database designed to include, with respect to each high-containment laboratory, the following information: (A) The identity of the owners of the laboratory. (B) The address of the laboratory. (C) The status of any licensing or certification of the laboratory required under Federal, State, local, Tribal, or territorial law. (D) Any legal violations by, and disciplinary action taken against, the laboratory. (E) Such additional information as the Federal entity identified under subsection (a) determines appropriate to protect biosafety and biosecurity. (3) Report to congress.--Upon completion of the feasibility study under this subsection, the Federal entity identified under subsection (a) shall submit to Congress a report on the results of such study. (f) Definition.--In this section, the term ``high-containment laboratory'' means a laboratory that is suitable for ``biosafety level 3'' or any higher biosafety level procedures, as defined in the latest edition of ``Biosafety in Microbiological and Biomedical Laboratories'' published by the Centers for Disease Control and Prevention and the National Institutes of Health (or any successor to such publication). <all>\n--- KONIEC DOKUMENTU ---\n\nPAMIĘTAJ: Twoja odpowiedź MUSI być wyłącznie poprawnym obiektem JSON. Nie dodawaj żadnych dodatkowych znaków, komentarzy ani tekstu przed znacznikiem '{' ani po znaczniku '}'. Cała odpowiedź musi być parsowalna jako JSON.\nNa podstawie POWYŻSZEGO dokumentu, wypełnij poniższą strukturę JSON:\nOto struktura JSON, której oczekuję (wypełnij ją treścią):\n{\n  \"pl_ai_title\": \"Nowy, krótki tytuł dla aktu prawnego po polsku, oddający sedno wprowadzanych zmian (np. maksymalnie 10-12 słów).\",\n  \"pl_summary\": \"2-3 zdania zwięzłego podsumowania treści aktu prawnego po polsku, napisane z perspektywy wpływu na życie codzienne obywateli.\",\n  \"pl_key_points\": [\n    \"Pierwszy krótki punkt po polsku dotyczący najważniejszych wprowadzanych rozwiązań lub zmian.\",\n    \"Drugi krótki punkt po polsku...\"\n  ],\n  \"eng_ai_title\": \"A new, short title for the legal act in English, capturing the essence of the changes (e.g., max 10-12 words).\",\n  \"eng_summary\": \"2-3 sentences summarizing the legal act in English, from the perspective of its impact on citizens' daily lives.\",\n  \"eng_key_points\": [\n    \"First short bullet point in English regarding the most important solutions or changes being introduced.\",\n    \"Second short bullet point in English...\"\n  ],\n  \"de_ai_title\": \"Ein neuer, kurzer Titel für das Rechtsdokument auf Deutsch, der den Kern der Änderungen erfasst (z.B. max. 10-12 Wörter).\",\n  \"de_summary\": \"2-3 Sätze Zusammenfassung des Rechtsdokuments auf Deutsch, aus der Perspektive seiner Auswirkungen auf das tägliche Leben der Bürger.\",\n  \"de_key_points\": [\n    \"Erster kurzer Stichpunkt auf Deutsch zu den wichtigsten eingeführten Lösungen oder Änderungen.\",\n    \"Zweiter kurzer Stichpunkt auf Deutsch...\"\n  ],\n  \"fr_ai_title\": \"Un nouveau titre court pour l'acte juridique en français, saisissant l'essence des changements (par exemple, 10-12 mots maximum).\",\n  \"fr_summary\": \"Résumé de 2-3 phrases de l'acte juridique en français, du point de vue de son impact sur la vie quotidienne des citoyens.\",\n  \"fr_key_points\": [\n    \"Premier court point en français concernant les solutions ou changements les plus importants introduits.\",\n    \"Deuxième court point en français...\"\n  ],\n  \"es_ai_title\": \"Un nuevo título breve para el acto jurídico en español, que recoja la esencia de los cambios (por ejemplo, máximo 10-12 palabras).\",\n  \"es_summary\": \"Resumen de 2-3 frases del acto jurídico en español, desde la perspectiva de su impacto en la vida cotidiana de los ciudadanos.\",\n  \"es_key_points\": [\n    \"Primer punto breve en español sobre las soluciones o cambios más importantes que se introducen.\",\n    \"Segundo punto breve en español...\"\n  ],\n  \"it_ai_title\": \"Un nuovo titolo breve per l'atto giuridico in italiano, che colga l'essenza delle modifiche (ad es. massimo 10-12 parole).\",\n  \"it_summary\": \"Riepilogo di 2-3 frasi dell'atto giuridico in italiano, dal punto di vista del suo impatto sulla vita quotidiana dei cittadini.\",\n  \"it_key_points\": [\n    \"Primo breve punto in italiano riguardante le soluzioni o le modifiche più importanti introdotte.\",\n    \"Secondo breve punto in italiano...\"\n  ],\n  \"nl_ai_title\": \"Een nieuwe, korte titel voor de rechtshandeling in het Nederlands, die de essentie van de wijzigingen weergeeft (bijv. max. 10-12 woorden).\",\n  \"nl_summary\": \"Samenvatting van 2-3 zinnen van de rechtshandeling in het Nederlands, vanuit het perspectief van de impact op het dagelijks leven van burgers.\",\n  \"nl_key_points\": [\n    \"Eerste korte punt in het Nederlands betreffende de belangrijkste geïntroduceerde oplossingen of wijzigingen.\",\n    \"Tweede korte punt in het Nederlands...\"\n  ],\n  \"pt_ai_title\": \"Um novo título curto para o ato jurídico em português, capturando a essência das mudanças (por exemplo, máx. 10-12 palavras).\",\n  \"pt_summary\": \"Resumo de 2-3 frases do ato jurídico em português, na perspetiva do seu impacto na vida quotidiana dos cidadãos.\",\n  \"pt_key_points\": [\n    \"Primeiro ponto curto em português sobre as soluções ou alterações mais importantes introduzidas.\",\n    \"Segundo ponto curto em português...\"\n  ],\n  \"category\": [\"Categorize the document into one category by default, based on the field it primarily concerns. Choose up to 3 if the document also touches upon SIGNIFICANT issues from other categories. You MUST select categories ONLY from the following list: Health, Education, Family, Taxes, Labor, Security, Environment, Courts and Law, Transport, Benefits, Real Estate, Media and Culture, Local Government, Migration, Agriculture, Public Investments, Informatization, Economy. If the document does not definitively fit any of these, you MUST use \"Other\". If you use \"Other\", it should be the ONLY category selected. Do NOT invent new categories. The response must be an array of strings, e.g., [\"Taxes\", \"Family\"].\"]\n}\n\n",
      "ai_response_raw": "{\n  \"pl_ai_title\": \"Ustawa o zapobieganiu nielegalnym laboratoriom i ochronie zdrowia publicznego z 2026 r.\",\n  \"pl_summary\": \"Ustawa wprowadza ścisłą kontrolę nad obrotem niebezpiecznymi patogenami oraz zwiększa nadzór nad laboratoriami o wysokim stopniu bezpieczeństwa. Obywatele zyskują większą ochronę przed ryzykiem wycieku groźnych substancji dzięki obowiązkowym rejestrom sprzedaży i ogólnokrajowym standardom bezpieczeństwa.\",\n  \"pl_key_points\": [\n    \"Obowiązkowe cyfrowe rejestry sprzedaży, najmu i przekazywania groźnych patogenów.\",\n    \"Wymóg weryfikacji tożsamości kupującego oraz podania celu użycia i miejsca przechowywania substancji.\",\n    \"Kary kryminalne za podawanie fałszywych informacji przy zakupie niebezpiecznych czynników biologicznych.\",\n    \"Utworzenie ogólnokrajowych standardów bezpieczeństwa dla laboratoriów wysokiego ryzyka.\",\n    \"Powołanie specjalnego zespołu federalnego jako punktu kontaktu dla władz lokalnych w sprawach bezpieczeństwa biologicznego.\"\n  ],\n  \"eng_ai_title\": \"Preventing Illegal Laboratories and Protecting Public Health Act of 2026\",\n  \"eng_summary\": \"This act establishes strict tracking for dangerous pathogens and increases oversight of high-security laboratories. It aims to protect public health by ensuring that hazardous biological agents are only sold to verified individuals for legitimate purposes.\",\n  \"eng_key_points\": [\n    \"Mandatory electronic logbooks for the sale, lease, or transfer of highly dangerous pathogens.\",\n    \"Requirement for identity verification and detailed descriptions of the purchaser's intended use and storage location.\",\n    \"Criminal penalties for providing false information when acquiring hazardous biological agents.\",\n    \"Establishment of national safety standards and strategic evaluations for high-containment laboratories.\",\n    \"Creation of a federal biosafety support team to assist state and local agencies with security concerns.\"\n  ],\n  \"de_ai_title\": \"Gesetz zur Verhinderung illegaler Labore und zum Schutz der öffentlichen Gesundheit 2026\",\n  \"de_summary\": \"Dieses Gesetz führt eine strenge Kontrolle des Handels mit gefährlichen Krankheitserregern ein und verstärkt die Aufsicht über Hochsicherheitslabore. Bürger profitieren von einem besseren Schutz vor biologischen Gefahren durch verpflichtende Verkaufsregister und nationale Sicherheitsstandards.\",\n  \"de_key_points\": [\n    \"Verpflichtende elektronische Logbücher für den Verkauf und die Übertragung gefährlicher Erreger.\",\n    \"Identitätsprüfung und Angabe des Verwendungszwecks sowie des Lagerorts beim Kauf.\",\n    \"Strafrechtliche Konsequenzen für Falschangaben beim Erwerb biologischer Gefahrenstoffe.\",\n    \"Einführung nationaler Sicherheitsstandards für Labore mit hoher Sicherheitsstufe.\",\n    \"Einrichtung eines zentralen federalen Ansprechpartners für lokale Behörden zur Biosicherheit.\"\n  ],\n  \"fr_ai_title\": \"Loi de 2026 sur la prévention des laboratoires illégaux et la protection de la santé publique\",\n  \"fr_summary\": \"Cette loi instaure un contrôle strict du commerce des agents pathogènes dangereux et renforce la surveillance des laboratoires de haute sécurité. Elle vise à protéger la population en garantissant que les substances biologiques risquées sont suivies et utilisées de manière légitime.\",\n  \"fr_key_points\": [\n    \"Registres électroniques obligatoires pour la vente, la location ou le transfert d'agents pathogènes dangereux.\",\n    \"Vérification de l'identité et description obligatoire de l'usage prévu et du lieu de stockage par l'acheteur.\",\n    \"Sanctions pénales en cas de fausses déclarations lors de l'acquisition d'agents biologiques.\",\n    \"Établissement de normes nationales de sécurité pour les laboratoires de haute sécurité.\",\n    \"Création d'une équipe fédérale d'appui pour conseiller les autorités locales sur la biosécurité.\"\n  ],\n  \"es_ai_title\": \"Ley de Prevención de Laboratorios Ilegales y Protección de la Salud Pública de 2026\",\n  \"es_summary\": \"Esta ley establece un control estricto sobre el comercio de patógenos peligrosos y aumenta la supervisión de los laboratorios de alta seguridad. Busca proteger la salud pública asegurando que los agentes biológicos de riesgo se vendan solo a personas verificadas para fines legítimos.\",\n  \"es_key_points\": [\n    \"Registros electrónicos obligatorios para la venta, alquiler o transferencia de patógenos altamente peligrosos.\",\n    \"Requisito de verificación de identidad y descripción del uso previsto y lugar de almacenamiento por parte del comprador.\",\n    \"Penas criminales por proporcionar información falsa al adquirir agentes biológicos peligrosos.\",\n    \"Establecimiento de estándares nacionales de seguridad para laboratorios de alta contención.\",\n    \"Creación de un equipo federal de apoyo en bioseguridad para asistir a las agencias locales.\"\n  ],\n  \"it_ai_title\": \"Legge del 2026 sulla prevenzione dei laboratori illegali e la protezione della salute pubblica\",\n  \"it_summary\": \"Questa legge introduce un controllo rigoroso sul commercio di agenti patogeni pericolosi e rafforza la vigilanza sui laboratori ad alta sicurezza. Mira a proteggere la salute pubblica garantendo che le sostanze biologiche a rischio siano tracciate e utilizzate correttamente.\",\n  \"it_key_points\": [\n    \"Registri elettronici obbligatori per la vendita, il noleggio o il trasferimento di agenti patogeni pericolosi.\",\n    \"Obbligo di verifica dell'identità e descrizione dell'uso previsto e del luogo di conservazione per ogni acquirente.\",\n    \"Sanzioni penali per chi fornisce informazioni false durante l'acquisto di agenti biologici a rischio.\",\n    \"Definizione di standard nazionali di sicurezza per i laboratori ad alto contenimento.\",\n    \"Creazione di un team federale di supporto alla biosicurezza per le autorità locali e statali.\"\n  ],\n  \"nl_ai_title\": \"Wet ter voorkoming van illegale laboratoria en bescherming van de volksgezondheid van 2026\",\n  \"nl_summary\": \"Deze wet voert een strikte controle in op de handel in gevaarlijke ziekteverwekkers en versterkt het toezicht op hoogbeveiligde laboratoria. Burgers worden beter beschermd tegen biologische risico's door verplichte verkoopregisters en nationale veiligheidsnormen.\",\n  \"nl_key_points\": [\n    \"Verplichte elektronische logboeken voor de verkoop, verhuur of overdracht van zeer gevaarlijke ziekteverwekkers.\",\n    \"Identiteitscontrole en verplichte opgave van het gebruiksdoel en de opslaglocatie door de koper.\",\n    \"Strafrechtelijke sancties voor het verstrekken van valse informatie bij de aanschaf van biologische agentia.\",\n    \"Vaststelling van nationale veiligheidsnormen voor laboratoria met een hoog beveiligingsniveau.\",\n    \"Oprichting van een federaal bioviligheidsteam als aanspreekpunt voor lokale overheden.\"\n  ],\n  \"pt_ai_title\": \"Lei de Prevenção de Laboratórios Ilegais e Proteção da Saúde Pública de 2026\",\n  \"pt_summary\": \"Esta lei estabelece um controlo rigoroso sobre o comércio de agentes patogénicos perigosos e reforça a supervisão de laboratórios de alta segurança. O objetivo é proteger a saúde pública, garantindo que substâncias biológicas de risco sejam vendidas apenas a pessoas verificadas para fins legítimos.\",\n  \"pt_key_points\": [\n    \"Registos eletrónicos obrigatórios para a venda, aluguer ou transferência de agentes patogénicos altamente perigosos.\",\n    \"Exigência de verificação de identidade e descrição do uso pretendido e local de armazenamento pelo comprador.\",\n    \"Sanções criminais por fornecer informações falsas ao adquirir agentes biológicos perigosos.\",\n    \"Estabelecimento de padrões nacionais de segurança para laboratórios de alta contenção.\",\n    \"Criação de uma equipa federal de apoio à biossegurança para auxiliar agências locais e estaduais.\"\n  ],\n  \"category\": [\"Health\", \"Security\"]\n}"
    }
  ]
}